
|Videos|May 7, 2021
Focusing on 24-month data of the PALADIN study
Author(s)OTE Staff Reports, David Hutton
Dr Michael A. Singer speaks on the highlights of his presentation focusing on IOP in the PALADIN 24-month data intravitreal steroid (ILUVIEN).
Advertisement
Dr Michael A. Singer of the Medical Center Ophthalmology Associates in San Antonio, Texas, speaks on the highlights of his presentation focusing on intraocular pressure (IOP) in the PALADIN 24-month data intravitreal steroid (ILUVIEN), presented during ARVO 2021.
Newsletter
Get the essential updates shaping the future of pharma manufacturing and compliance—subscribe today to Pharmaceutical Technology and never miss a breakthrough.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Ophthalmology Times Europe
1
FLORetina 2025: Artificial intelligence at the frontlines of ROP care
2
FLORetina 2025: Port delivery system shows reliable 6-month durability and sustained efficacy in neovascular AMD for up to 7 years
3
FLORetina 2025: Fibrosis, a limiting factor in visual acuity outcomes in neovascular AMD
4
FLORetina 2025: Weight and PMA drive foveal maturation in preterm infants
5













































